in the news

The Path to Reemergence

Dino Muzzin, senior vice president of manufacturing operations at Emergent BioSolutions recently shared his insights with Pharma Manufacturing on lessons learned from COVID, and the path forward to future pandemic preparedness.

Read the full article here

 

CITATION

K. Langhauser, "Emergent BioSolutions: The path to reemergence," Pharma Manufacturing, February 10, 2022.

Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate

  • Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large...
READ MORE

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

  • Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...
READ MORE

SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions

SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a...

READ MORE